Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial - Patil, ST; Zhang, L; Martenyi, F; Lowe, SL; Jackson, KA; Andreev, BV; Avedisova, AS; Bardenstein, LM; Gurovich, IY; Morozova, MA; Mosolov, SN; Neznanov, NG; Reznik, AM; Smulevich, AB; Tochilov, VA; Johnson, BG; Monn, JA; Schoepp, DD (Nat Med, 2007)